Figure 5 | Scientific Reports

Figure 5

From: Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma

Figure 5

Effects of tyrosine kinase inhibitors that targets FGFR1, ponatinib. (a) Growth inhibitions by ponatinib in canine histiocytic sarcoma cell lines, DHS-1 and DHS-2. (b) The representative figure that shows changes in the amounts of phosphorylated ERK1/2 (pERK) and AKT (pAkt) after treatments of ponatinib (Pona). This figure was prepared by cropping the images of the bands indicating each antigen from the figures shown in Additional file 1: Fig. S6. (c) The result of statistical comparison by density analysis for Western blot in triplicate. Although the amounts of pERK and pAKT were not changed after treatment with Pona in DHS1, those in DHS2 were decreased by treatment with ponatinib. ***P < 0.0001.

Back to article page